Johnson & Johnson launches late-stage trial for COVID-19 vaccine

Johnson & Johnson launches late-stage trial for COVID-19 vaccine


Johnson & Johnson has launched a late-stage trial for its second COVID-19 vaccine, a report said Monday.

The New Jersey-based drugmaker had already been conducting a stage-three trial for a vaccine that is administered in a single dose. This new late-stage trial is for a second Johnson & Johnson vaccine that involves two doses, according to the website BioPharma-Reporter.

The new trial will try to determine how effective the second dose may be in extending immunity, the site said.

Trending: Breaking News: Over 6,000 False Biden Votes Discovered in Arizona Ballot Count Upload Error (Lead dips under 5,000)

Testing on J&J’s single-dose vaccine began in September and involves 60,000 people from the US, Mexico, South Africa and several countries in South America.

The newly launched two-dose immunization trial has 30,000 participants from countries including the US, Britain, France, Germany, Spain and the Philippines.

The news comes as a second coronavirus vaccine has shown remarkable results from its stage-three trial.

That vaccine, developed by Moderna, appears to be nearly 95 percent effective based on test results, the company announced

Continue reading

You Might Like

Do NOT follow this link or you will be banned from the site!
Send this to a friend